[1]黄倩云,李长钢.门冬酰胺酶对白血病患儿静脉血栓形成的研究进展[J].医学信息,2018,31(12):39-42.[doi:10.3969/j.issn.1006-1959.2018.12.013]
　HUANG Qian-yun,LI Chang-gang.Advances in the Treatment of Venous Thrombosis in Children with Leukemia by Asparaginase[J].Journal of Medical Information,2018,31(12):39-42.[doi:10.3969/j.issn.1006-1959.2018.12.013]
点击复制

门冬酰胺酶对白血病患儿静脉血栓形成的研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年12期
页码:
39-42
栏目:
综述
出版日期:
2018-06-15

文章信息/Info

Title:
Advances in the Treatment of Venous Thrombosis in Children with Leukemia by Asparaginase
文章编号:
1006-1959（2018）12-0039-04
作者:
黄倩云1; 李长钢2
1.遵义医学院珠海校区，广东 珠海 519041； 2.遵义医学院附属深圳市儿童医院，广东 深圳 518038
Author(s):
HUANG Qian-yun1; LI Chang-gang2
1.Zhuhai Campus of Zunyi Medical College,Zhuhai 519041,Guangdong,China; 2.Shenzhen Children’s Hospital,Zunyi Medical College,Shenzhen 518038,Guangdong,China
关键词:
门冬酰胺酶; 静脉血栓形成; 急性淋巴细胞白血病
Keywords:
Key words：Asparaginase; Venous thrombosis; Acute lymphoblastic leukemia
分类号:
R733.7
DOI:
10.3969/j.issn.1006-1959.2018.12.013
文献标志码:
A
摘要:
门冬酰胺酶在联合化疗中的应用使儿童急性淋巴细胞性白血病成为可治愈的恶性肿瘤。但ASP导致血栓形成可影响患者化疗进程，降低化疗缓解率。静脉血栓形成的发病率在1%~36%，主要取决于患者年龄、治疗方案、血栓筛检方法的不同。血栓形成的部位主要在上肢静脉，尤其是中心静脉导管。ASP导致血栓形成的机制是通过降低AT-Ⅲ水平，及激活血小板和内皮细胞。年龄、中心静脉导管、激素及遗传因素均是影响血栓发生的高危因素。预防性使用AT-Ⅲ或LWMH可降低静脉血栓形成的风险。新型口服抗凝药物，是凝血酶或Xa因子直接抑制剂，其抗凝效果不依赖AT-Ⅲ水平，由此推测，新型抗凝剂比传统抗凝剂在预防门冬酰胺酶相关性血栓形成更为有效和更便于临床应用。
Abstract:
Abstract：Application of asparaginase in combination chemotherapy makes childhood acute lymphoblastic leukemia a curable malignant tumor.However,ASP caused thrombosis can affect the chemotherapy process and reduce the remission rate of chemotherapy.The incidence of venous thrombosis varies from 1%~36%,depending on the age of patients,treatment options,and screening methods for thrombosis.The site of thrombosis is mainly in the veins of the upper extremities,especially the central venous catheters.The mechanism by which ASP causes thrombosis is by lowering AT-III levels and activating platelets and endothelial cells. Age,central venous catheter,hormones and genetic factors are all high risk factors for thrombosis.Prophylactic use of AT-III or LWMH reduces the risk of venous thrombosis.The new anticoagulant is a direct inhibitor of thrombin or Xa factor.Its anticoagulant effect does not depend on the level of AT- III.Thus,it is speculated that the new anticoagulant is more effective and more convenient for clinical application than the traditional anticoagulant in preventing the formation of asparaginase related thrombus.

参考文献/References:

[1]Koprivnikar J,Mccloskey J,Faderl S.Safety,efficacy and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia[J].Oncotargets&Therapy,2017(10):1413-1422.
[2]Thu VH,Bergeron S.Asparaginase Toxicities:Identification and Management in Patients With Acute Lymphoblastic Leukemia[J].Clinical Journal of Oncology Nursing,2017,21(5):E248.
[3]De Stefano V,Za T,Ciminello A,et al.Haemostatic alterations induced by treatment with asparaginases and clinical consequences[J].Thromb Haemost,2015(113):247-261.
[4]Grace RF,Dahlberg SE,Neuberg D,et al.The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols[J].British Journal of Haematology,2011,152(4):452-459.
[5]Caruso V,Iacoviello L,Di CA,et al.Thrombotic complications in childhood acute lymphoblastic leukemia:a meta-analysis of 17 prospective studies comprising 1752 pediatric patients[J].Blood,2006,108(7):2216-2222.
[6]Hunault-Berger M,Chevallier P,Delain M,et al.Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.Use of supportive coagulation therapy and clinical outcome:the CAPELAL study[J].Haematologica,2008,93(10):1488.
[7]Couturier MA,Huguet F.Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase:The GRAALL experience[J].Am J Hematol,2015,90(11):986-991.
[8]Nobuko Hijiya,Inge M.van der Sluis.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia[J].Leukemia&Lymphoma,2016,57(4):748-757.
[9]Chopra V,Anand S,Hickner A,et al.Risk of venous thromboembolism associated with peripherally inserted central catheters:a systematic review and meta-analysis[J].Lancet,2013,382(9889):311-325.
[10]Santoro N,Colombini A,Silvestri D,et al.Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis:an AIEOP experience[J].Journal of Pediatric Hematology oncology,2013,35(5):348-355.
[11]Mizrahi T,Leclerc J M,David M,et al.ABO Group as a Thrombotic Risk Factor in Children With Acute Lymphoblastic Leukemia:A Retrospective Study of 523 Patients[J].Journal of Pediatric Hematology oncology,2015,37(5):328-332.
[12]Rozen L,Noubouossie D,Dedeken L,et al.Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase:A cohort study[J].Pediatric Blood&Cancer,2016,64(2):294.
[13]Domenech C,Thomas X,Chabaud S,et al.lasparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults:results of the GRASPALL 2005-01 randomized trial[J].Br J Haematol,2011,153(1):58-65.
[14]Hakoum MB,Kahale LA,Tsolakian IG,et al.Anticoagulation for the initial treatment of venous thromboembolism in people with cancer[J].Cochrane Database Syst Rev,2018,24(1):CD006649.
[15]Lee AYY,Levin MN,Bake RI,et al.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J].N Engl J Med,2003(349):146-153.
[16]Bennett ST.Monitoring of Anticoagulant Therapy[M].Laboratory Hemostasis.Springer International Publishing,2015:135-171.
[17]Vedovati M C,Germini F,Agnelli G,et al.Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Cancer:A Systematic Review and Meta-Analysis[J].Chest,2015,147(2):475-483.
[18]Kuhle S,Lau A,Bajzar L,et al.Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with lasparaginase:an in vitro study[J].Br J Haematol,2006,134(5):526-531.
[19]Savage SA,Young G,Reaman GH.Catheter-directed thrombolysis in a child with acute lymphoblastic leukemia and extensive deep vein thrombosis.[J].Pediatric Blood&Cancer,2015,34(3):215-217.
[20]Elhasid R,Lanir NR,Weyl M,et al.Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia[J].Blood Coagul Fibrinolysis,2001,12(5):367-370.
[21]Meister B,Kropshofer G,Kleinfranke A,et al.Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia[J].Pediatric Blood&Cancer,2010,50(2):298-303.

更新日期/Last Update: 2018-06-15